AstraZeneca PLC (LON:AZN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of AstraZeneca PLC (LON:AZN) have received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is £153.33.

AZN has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating and issued a £115 price objective on shares of AstraZeneca in a research note on Tuesday, June 2nd. Citigroup lifted their price objective on shares of AstraZeneca from £170 to £180 and gave the company a “buy” rating in a research note on Friday, April 10th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a £180 price objective on shares of AstraZeneca in a research note on Wednesday, May 13th.

AstraZeneca Trading Down 0.5%

Shares of LON:AZN opened at £137.90 on Monday. The firm has a fifty day moving average of £141.97 and a two-hundred day moving average of £141.40. The firm has a market capitalization of £213.86 billion, a P/E ratio of 20.77, a price-to-earnings-growth ratio of 0.86 and a beta of 0.22. AstraZeneca has a 12-month low of £101.03 and a 12-month high of £157.32. The company has a quick ratio of 0.59, a current ratio of 0.91 and a debt-to-equity ratio of 71.66.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.